Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Rigel Pharmaceuticals Inc. (New)

RIGL

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.

Last trade $42.56
Day change -$1.17 (-2.68%)
Day range $41.88 – $43.71
Volume 122,895
Market cap $823M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$823.43M
Price / earnings
2.68×
Price / book
1.85×
Price / sales
2.86×
EV / sales
2.72×
EV / EBITDA
9.85×

Profitability

Earnings per share
$16.31
Return on assets
58.64%
Return on equity
69.02%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.02×
Current ratio
2.39×
Quick ratio
2.19×
Cash ratio
0.59×

Cash flow

Price / cash flow
9.16×
Price / free cash flow
9.16×
Free cash flow
$89.91M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for RIGL, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$80.89M$78.7M$58.82M$69.8M$69.46M$101.69M$53.33M$57.6M
Cost of revenue$10.78M$8.53M$4.61M$5.96M$4.75M$4.5M$4.41M$5.79M
Gross profit$70.11M$70.18M$54.21M$63.85M$64.71M$97.18M$48.92M$51.81M
Selling, general and administrative$34.73M$32.64M$30.65M$29.99M$28.94M$29.26M$27.72M$29.52M
Research and development$18.27M$13.96M$11.68M$10.69M$7.35M$6.82M$8.44M$5.63M
Total operating expenses$53M$46.6M$42.33M$40.68M$36.29M$36.08M$36.15M$35.15M
Operating income$17.11M$23.58M$11.89M$23.17M$28.42M$61.1M$12.77M$16.66M
Interest expense-$257K-$779K-$1.43M-$1.7M-$1.89M-$1.87M-$1.85M-$1.96M
Income before taxes$17.41M$23.59M$11.66M$22.71M$27.62M$59.98M$11.51M$15.22M
Income taxes$4.22M$6.3M$3M-$245.35M-$280K$369K$65K$881K
Net income$13.19M$17.29M$8.65M$268.07M$27.9M$59.61M$11.45M$14.34M
Net income attributable to common shareholders$13.19M$17.29M$8.65M$268.07M$27.9M$59.61M$11.45M$14.34M
EBITDA$18.9M$24.42M$12.48M$23.77M$29.02M$61.71M$13.38M$17.26M
Basic earnings per share$0.70$0.93$0.47$14.72$1.55$3.33$0.64$0.81
Diluted earnings per share$0.65$0.88$0.44$13.49$1.46$3.28$0.63$0.80

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Arvinas to Present at Jefferies Global Healthcare Conference

Arvinas, a clinical-stage biotech company specializing in protein degradation therapies, announced management participation in a fireside chat at the Jefferies Global Healthcare Conference on November 18, 2026. The company will present preliminary clinical data from early monotherapy dose escalation cohorts of ARV-393 (Zaloblideg), a PROTAC BCL6 degrader, at the 2026 American Society of Hematology Annual Meeting, including safety, pharmacokinetics, and pharmacodynamics data.

Zacks Investment Research

Rigel Pharmaceuticals (RIGL) Misses Q3 Earnings Estimates

Rigel Pharmaceuticals (RIGL) reported quarterly earnings of $0.65 per share, missing the consensus estimate of $0.87 per share, representing a -25.29% earnings surprise. However, the company exceeded revenue expectations with $80.89 million versus the estimate of $78.27 million. The stock received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market. Marker Therapeutics (MRKR) is expected to report a quarterly loss of $0.12 per share with revenues of $2.45 million.

Zacks Investment Research

United Therapeutics (UTHR) Q3 Earnings Miss Estimates

United Therapeutics reported Q3 2026 earnings of $5.71 per share, missing the consensus estimate of $5.85, representing a -2.39% surprise. However, the company exceeded revenue expectations with $832.5 million versus the estimate of $783.3 million. The stock received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market. The Medical - Drugs industry ranks in the top 41% of Zacks industries.

Zacks Investment Research

Reasons Why Investors Should Consider Betting on Arvinas Stock

Arvinas received FDA approval for Veppanu (vepdegestrant) in May 2026, marking the first FDA-approved PROTAC protein degrader for treating ESR1-mutated breast cancer. The company out-licensed global rights to Rigel Pharmaceuticals for $70 million upfront plus up to $320 million in milestones and royalties. Arvinas' diversified pipeline includes candidates for lymphoma, Parkinson's disease, and solid tumors with data expected through 2027.

GlobeNewswire Inc.

Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company’s First Immuno-Oncology Candidate

Arvinas announced the first patient dosing in a Phase 1/2 clinical trial of ARV-6723, an oral PROTAC designed to degrade HPK1 for advanced solid tumors. The drug is Arvinas' first immuno-oncology candidate and the first HPK1 PROTAC degrader to enter clinical trials in the US. Preclinical data showed potent HPK1 degradation, enhanced immune activity, and antitumor effects as monotherapy and in combination with anti-PD-1 therapy, including activity in anti-PD-1-resistant models.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Jun 27, 20241-for-10reverse split
Jun 25, 20031-for-9reverse split